Article Text

Download PDFPDF
Short course treatment for MDR TB: jumping the gun?
  1. Anna Turkova1,
  2. Beate Kampmann2
  1. 1 MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK
  2. 2 Imperial College London, UK and MRC Unit The Gambia, West Africa
  1. Correspondence to Professor Beate Kampmann, Imperial College London and MRC Unit The Gambia, St Mary's Campus, Wright-Fleming Building 2nd floor, Room 220, Norfolk Place, London W2 1PG, UK; b.kampmann{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Multidrug-resistant (MDR)-TB is threatening TB control worldwide. The conventional treatment lasts 20–24 months, is often toxic and half of the treated patients have poor outcomes. WHO has recently recommended a shorter regimen with treatment duration of 9–12 months, aiming for higher effectiveness, tolerability, adherence and completion rates.1 This shorter regimen is recommended for patients with pulmonary TB who have not been previously exposed to second-line drugs for more than 1 month and have no confirmed or suspected resistance to drugs in the regimen, except high-dose isoniazid. Recommendations were based on the promising results of large observational cohorts in Asia and Africa.

In Thorax, Yanina Balabanova and colleagues assessed the proportion of adult smear-positive pulmonary MDR-TB cases who might have …

View Full Text


  • Contributors This is a jointly written and approved editorial.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles